Keyphrases
Tumor Uptake
100%
Lymphoma
100%
Rituximab
100%
Iodine-131 (131I)
100%
CD20-negative
100%
Therapeutic Agents
50%
Mantle Cell Lymphoma
50%
Radioimmunotherapy
50%
Diagnostic Dose
50%
Treatment Modalities
25%
Cell Population
25%
B Cells
25%
Young Males
25%
Tumor Location
25%
Flow Cytometric Analysis
25%
B-cell non-Hodgkin Lymphoma (B-NHL)
25%
18F-fluorodeoxyglucose (18F-FDG)
25%
Lymph Node
25%
Implications for Treatment
25%
Diagnostic Imaging
25%
Dose Verification
25%
Left Arm
25%
Appropriate Dose
25%
Radiolabeled Compounds
25%
Medicine and Dentistry
Neoplasm
100%
Rituximab
100%
Iodine 131
100%
CD20
100%
Diagnosis
50%
B Cell
50%
Mantle Cell Lymphoma
50%
Radioimmunotherapy
50%
Cell Population
25%
Arm
25%
Non-Hodgkin Lymphoma
25%
Fluorodeoxyglucose F 18
25%
Radioactive Tracer
25%
Lymph Node
25%
Diagnostic Imaging
25%
Immunology and Microbiology
CD20
100%
Rituximab
100%
Iodine-131
100%
B Cell
50%
Lymphoma Cell
50%
Cell Population
25%
Lymph Node
25%
Arm
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Rituximab
100%
Iodine-131
100%
Mantle Cell Lymphoma
50%
Tracer
25%
Fluorodeoxyglucose F 18
25%
Nonhodgkin Lymphoma
25%
Neuroscience
CD20
100%
Rituximab
100%
B Cell
50%
Lymph Node
25%
Non-Hodgkin Lymphoma
25%